Since Lundbeck went through a larger shift in its research and development division, the company has been busy scouting for assets that could fit in its new focus area, neuroinflammation or neuroimmunology.
This has resulted in the purchase of the phase I-ready antibody APB-A1 from the South Korean company Aprilbio, and Lundbeck's Head of Research and Development Johan Luthman is excited to finally have the first real candidate in the company's new area.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.